Fitness in Elderly AML Patients
NCT07598838 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 725
Last updated 2026-05-22
Summary
The study aims to evaluate the outcome of patients (overall survival) who received treatments commensurate with the proposed "Fitness" parameters compared to that of patients whose treatment differed either in the direction of greater or lesser aggressiveness than that proposed (evaluation of survival through Kaplan-Meier analysis and comparison with the log-rank test).
Conditions
- AML (Acute Myelogenous Leukemia
Interventions
- OTHER
-
Fitness Categories: FIT, UNFIT and FRAIL
fitness categories and treatment received
Sponsors & Collaborators
-
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
lead OTHER
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-01
- Primary Completion
- 2025-06-30
- Completion
- 2026-05-30
Countries
- Italy
Study Locations
More Related Trials
-
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
NCT06764459 ·Status: RECRUITING
-
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
NCT06379360 ·Status: RECRUITING ·Phase: PHASE2
-
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML
NCT03620955 ·Status: UNKNOWN
-
Assessing Refractoriness and Infectious Survival Events in AML
NCT06709235 ·Status: COMPLETED
-
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916 ·Status: RECRUITING
-
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
NCT07463651 ·Status: RECRUITING ·Phase: PHASE3
-
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
NCT03298984 ·Status: COMPLETED ·Phase: PHASE1
-
Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia
NCT04641910 ·Status: COMPLETED
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia
NCT00510939 ·Status: UNKNOWN ·Phase: PHASE2
-
Sorafenib to Treat FLT3-ITD AML
NCT02156297 ·Status: UNKNOWN
-
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
NCT01051063 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
NCT06651866 ·Status: RECRUITING ·Phase: PHASE1
-
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
NCT03170895 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
NCT03823352 ·Status: COMPLETED ·Phase: PHASE2
-
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
NCT03789981 ·Status: ACTIVE_NOT_RECRUITING
-
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT06652685 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia
NCT02844218 ·Status: COMPLETED
-
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
NCT02348489 ·Status: COMPLETED ·Phase: PHASE3
-
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01371981 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
NCT04827069 ·Status: COMPLETED ·Phase: PHASE1
-
Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain
NCT03435341 ·Status: COMPLETED
-
Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
NCT03715621 ·Status: UNKNOWN
-
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
NCT03047083 ·Status: COMPLETED
-
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
NCT06130787 ·Status: RECRUITING ·Phase: NA